#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Testicular leiomyosarcoma Plasma cell myeloma refractory Myotonic dystrophy Alport's syndrome Progressive familial intrahepatic cholestasis Shprintzen-Goldberg syndrome Atypical haemolytic uraemic syndrome Congenital pseudarthrosis Kearns-Sayre syndrome Anaplastic thyroid cancer Hereditary angioedema with C1 esterase inhibitor deficiency Hypotransferrinaemia Choroidal dystrophy Pulmonary alveolar haemorrhage Chronic lymphocytic leukaemia refractory More trials…

    Learn about Rare Diseases

    Sjogren’s syndrome Undifferentiated sarcoma – Treatment Chronic granulomatous disease – Basic Information Hypereosinophilic syndrome – Diagnostics Aicardi-Goutieres syndrome Haemophilia B with anti factor IX – Diagnostics Gaucher’s disease type I – Diagnostics Mantle cell lymphoma stage IV – Trials in Disease Malignant fibrous histiocytoma – Diagnostics Biotinidase deficiency More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Povidone, Iodinated Rozanolixizumab Bilastine Allo-501A Gremubamab HUMAN PLASMA Digitoxin Icatibant Acetylsalicylic Acid Dronedarone Sar444656 Pbf-999 CAL101 GSKVX000000034797 Tropicamide Astegolimab 18F-Psma-1007 Iomeprol Darunavir Yttrium-90 More therapies…

    Learn about Your Condition

    Mucosal inflammation Ocular lymphoma Irritable bowel syndrome Ovarian cancer metastatic Thrombocytosis Muscular dystrophy Systemic lupus erythematosus Stomatitis Upper limb fracture Wheezing Prodromal Alzheimer's disease Intermittent claudication Neonatal asphyxia Emphysema Breast angiosarcoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Hautarztpraxis Dr. Mihaescu

Hautarztpraxis Dr. Mihaescu

Froelichstrasse 8, Augsburg, 86150, Germany

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Long-Term Safety and Efficacy of Amlitelimab for Patients with Moderate to Severe Atopic Dermatitis from Previous Trials

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Amlitelimab
    Bulgaria Czechia Denmark France Germany Greece +7

  • Study on the Effectiveness and Safety of PQ Birch for Patients with Seasonal Allergic Rhinitis or Rhinoconjunctivitis from Birch Pollen

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Conjunctivitis allergic
    Investigated Drugs:
    • Placebo
    Austria Germany Poland

  • A Study of KT-621 Tablets Taken by Mouth for Adults with Moderate to Severe Atopic Dermatitis

    Not recruiting

    2 1
    Czechia Germany Poland

  • Study on the Effectiveness and Safety of ESK-001 and Apremilast for Adults with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Apremilast
    • Envudeucitinib
    Belgium Bulgaria Czechia Germany Poland Portugal

  • Study of amlitelimab injection compared to placebo for adults with severe alopecia areata (hair loss)

    Not recruiting

    2 1
    Investigated Diseases:
    • Alopecia areata
    Investigated Drugs:
    • Amlitelimab
    Bulgaria Czechia France Germany Italy The Netherlands +2

  • Study on Rezpegaldesleukin for Treating Moderate-to-Severe Atopic Dermatitis in Adults

    Not recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Rezpegaldesleukin
    Bulgaria Croatia Czechia Germany Hungary Poland +1

  • Study on the Effectiveness and Safety of Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis Using Topical Corticosteroids

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Amlitelimab
    • Pimecrolimus
    • Tacrolimus
    Bulgaria Czechia France Germany Italy Spain

  • Study on Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Amlitelimab
    • Pimecrolimus
    • Tacrolimus
    Bulgaria Czechia Denmark France Germany Greece +5

  • Study on the Effectiveness and Safety of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Lebrikizumab
    Germany The Netherlands

  • Study on the Long-term Safety and Effectiveness of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Lebrikizumab
    Germany Poland

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!